US/UK/Canada

Share

Contacts

  • Roland Frösing

    Acting CEO


    +46 723 20 61 00
  • Torbjörn Sannerstedt

    Acting CFO


    +46 708 66 22 55

    • Links

    Quotes

    The fact that ChloraSolv, with very good efficacy, now can be used on venous leg ulcers and diabetic foot ulcers is very positive, not only for the patients and relatives but also for healthcare and society as this patient group is connected with large healthcare costs.
    Karin Fischer, CEO, RLS Global
    We are pleased to receive a positive confirmation from Lloyd’s register that ChloraSolv satisfies all required technological requirements.
    Karin Fischer, CEO of RLS Global
    RLS now has a detailed plan with activities for bringing ChloraSolv to the European markets in a structured manner.
    Karin Fischer, CEO
    Pick a time period -
    Tags ( Active)

    RLS Global announces management change

    Karin Fischer has given notice that she intends to resign as CEO of RLS Global AB (publ). The Board has initiated the search for a new, R&D-focused CEO and Karin Fischer will continue in her role, until a new CEO has been appointed, to ensure a smooth succession.RLS Global (“RLS”) has over the past few years, under Karin Fischer’s leadership, transformed into a commercial stage wound care company. The expansion in Europe is well underway through our partnership with ConvaTec, which is responsible for the commercialization of ChloraSolv in these markets. European regulatory approval for

    RLS Global AB secures financing of SEK 20 million

    RLS Global has today signed a credit facility, on market terms, of SEK 20 million to create flexible financing for the company’s continued growth. It is one of the company’s major shareholders that has provided this credit facility.As of today, RLS has also received its first order from ConvaTec. As of January 1, 2022, ConvaTec will take ownership of the commercial process for ChloraSolv in Europe. The launch of ChloraSolv will take place in various stages with focus during 2022 in the Nordic countries, the Netherlands, the United Kingdom, Germany and France. ”I am pleased that RLS has

    RLS Global clinical study, ChloraSolv01, published in the Journal of Wound Care

    RLS Global is pleased to announce that the outcome of the completed clinical study ChloraSolv01 is published today in the Journal of Wound Care Vol 30, No 6, June 2021. Data from this clinical study show that a treatment regimen based on ChloraSolv could represent a valuable treatment option for patients suffering from hard-to-heal wounds.The wounds that were treated in the ChloraSolv01 clinical study were hard-to-heal, lower extremity ulcers which had more than 50% coverage of devitalized tissue. Using ChloraSolv once a week for 5 weeks resulted in a 73% reduction of the devitalized tissue

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe